ENTA — Enanta Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $444.20m
- $398.48m
- $65.32m
- 25
- 10
- 99
- 41
Annual cashflow statement for Enanta Pharmaceuticals, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -79 | -122 | -134 | -116 | -81.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 19 | 27.2 | 20.3 | 27.8 | 18.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -13.7 | 6.79 | 8.02 | 7.13 | 39.9 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -70 | -84.8 | -103 | -78.8 | -19.3 |
| Capital Expenditures | -0.75 | -2.13 | -9.06 | -17.9 | -12.9 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 37.7 | 57 | -44.5 | 76.2 | 53.2 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 37 | 54.9 | -53.6 | 58.2 | 40.3 |
| Financing Cash Flow Items | -0.534 | -1.23 | 196 | -0.294 | -0.277 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.08 | 20 | 198 | -27.6 | -26.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -29.9 | -9.85 | 41.4 | -48.2 | -5.54 |